LabTube is no longer active

LabTube is no longer accepting new video uploads, and will shortly be rolled down.

On our parent publication, Technology Networks, you’ll be able to find videos covering a range of topics across the life sciences, applied markets, analytical sciences, drug discovery and more. Click here to learn more.

Trending with Impact: DNA Markers Distinguish Sarcopenia from Frailty



September 16, 2021

  • Share
  • Aging-US published this trending research paper - selected as the cover for Volume 13, Issue 17 - on September 7, 2021, entitled, “Reduced uremic metabolites are prominent feature of sarcopenia, distinct from antioxidative markers for frailty” by researchers from the Geriatric Unit, Graduate School of Medicine, Kyoto University, Kyoto, Japan; G0 Cell Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Okinawa, Japan. Abstract Due to global aging, frailty and sarcopenia are increasing. Sarcopenia is defined as loss of volume and strength of skeletal muscle in elderlies, while frailty involves multiple domains of aging-related dysfunction, impaired cognition, hypomobility, and decreased social activity. However, little is known about the metabolic basis of sarcopenia, either shared with or discrete from frailty. Here we analyzed comprehensive metabolomic data of human blood in relation to sarcopenia, previously collected from 19 elderly participants in our frailty study. Among 131 metabolites, we identified 22 sarcopenia markers, distinct from 15 frailty markers, mainly including antioxidants, although sarcopenia overlaps clinically with physical frailty. Notably, 21 metabolites that decline in sarcopenia or low SMI are uremic compounds that increase in kidney dysfunction. These comprise TCA cycle, urea cycle, nitrogen, and methylated metabolites. Sarcopenia markers imply a close link between muscle and kidney function, while frailty markers define a state vulnerable to oxidative stress. Sign up for free Altmetric alerts about this article - DOI - Full text - Correspondence to: Mitsuhiro Yanagida email: Keywords: sarcopenia, muscle mass, metabolomics, frailty, uremic metabolites, aging About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at​​ or connect with us on: Twitter - Facebook - SoundCloud -​ YouTube -​ LinkedIn -​ Aging-US is published by Impact Journals, LLC please visit​​ or connect with @ImpactJrnls Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

    Cancer ResearchCell ScienceGenomicsMicrobiology

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.